TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25576353

Group type: EXPERIMENTAL
Intervention: Bevacizumab + chemotherapy
Number of subjects: 1967
Study: 25576647

Group type: EXPERIMENTAL
Intervention: Neural impulse control measured in the dorsolateral prefrontal cortex (DLPFC) using fMRI at T0 (beginning of follow-up) and T12 (end of follow-up).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavioral measures of control during the follow-up period.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neural signals from DLPFC.
Number of subjects: 0
Study: 25577718

Group type: EXPERIMENTAL
Intervention: Sunitinib, sorafenib, axitinib, temsirolimus, or temsirolimus and interferon-α
Number of subjects: 2749
Study: 25578404

Group type: EXPERIMENTAL
Intervention: WELCH score with a cut-off point of 25
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: WELCH score
Number of subjects: 525
Study: 25579459

Group type: EXPERIMENTAL
Intervention: Neoadjuvant anthracycline regimens followed by nanoparticle albumin-bound paclitaxel (nab-PTX) 260 mg/m² plus trastuzumab, administered every 3 weeks for 4 cycles.
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Neoadjuvant anthracycline regimens followed by nanoparticle albumin-bound paclitaxel (nab-PTX) plus trastuzumab.
Number of subjects: 44
Study: 25579693

Group type: EXPERIMENTAL
Intervention: OsteoACTIVE rehabilitation program (weight vests and patient education)
Number of subjects: 42
Study: 25579865

Group type: EXPERIMENTAL
Intervention: Endotoxin challenge (1 ng/kg LPS)
Number of subjects: 148
Study: 25581108

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 1192

Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 1192

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 1192

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 1192

Group type: COMPARATOR
Intervention: Nonvitamin K antagonist oral anticoagulants
Number of subjects: 1192

Group type: EXPERIMENTAL
Intervention: Nonvitamin K antagonist oral anticoagulants started early (median 4 days after stroke onset)
Number of subjects: 1192
Study: 25581596

Group type: EXPERIMENTAL
Intervention: Postoperative SIB-IMRT
Number of subjects: 201

Group type: COMPARATOR
Intervention: Non-RT (no postoperative RT)
Number of subjects: 201
Study: 25583164

Group type: EXPERIMENTAL
Intervention: Sofosbuvir and ribavirin for 12 or 24 weeks
Number of subjects: 497

Group type: COMPARATOR
Intervention: HCV-monoinfected patients
Number of subjects: 497
Study: 25583442

Group type: COMPARATOR
Intervention: Control group (glucose-tolerant)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes group
Number of subjects: 54
Study: 25584134

Group type: EXPERIMENTAL
Intervention: Ingenol mebutate 0.05% gel applied for two consecutive days to treatment areas up to 100cm(2)
Number of subjects: 81
Study: 25584193

Group type: EXPERIMENTAL
Intervention: Core strength training on unstable surfaces (CSTU)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Core strength training on stable surfaces (CSTS)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Core strength training (CSTU and CSTS combined)
Number of subjects: 27
Study: 25585031

Group type: EXPERIMENTAL
Intervention: 2013 AHA/ACC guidelines approach (maximization of statin therapy at high-intensity for patients aged ≤75 years and moderate- or high-intensity for patients >75 years)
Number of subjects: 1602

Group type: COMPARATOR
Intervention: Previous guidelines approach (achievement of LDL-C target < 1.8 mmol/l, reduction of LDL-C ≥ 50% or intensification of statin)
Number of subjects: 1602
Study: 25585528

Group type: EXPERIMENTAL
Intervention: Etravirine 400 mg and darunavir/ritonavir 800/100 mg once-daily regimen
Number of subjects: 54
Study: 25585572

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 144
Study: 25586396

Group type: EXPERIMENTAL
Intervention: Psilocybin administered orally in one or two supervised sessions in addition to Motivational Enhancement Therapy
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Psilocybin session intensity
Number of subjects: 10
Study: 25586626

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass surgery (n=76)
Number of subjects: 139

Group type: COMPARATOR
Intervention: intensive lifestyle intervention (n=63)
Number of subjects: 139
Study: 25586686

Group type: EXPERIMENTAL
Intervention: T2 magnetic resonance (T2MR)
Number of subjects: 1801
Study: 25586726

Group type: EXPERIMENTAL
Intervention: ϵ-aminocaproic acid (EACA)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dosing recommendations for EACA based on weight: weight <25 kg, 100 mg kg(-1) loading dose and 40 mg kg(-1) h(-1) infusion; weight ≤25 kg-<50 kg, 100 mg kg(-1) loading dose and 35 mg kg(-1) h(-1) infusion; weight ≥50 kg, 100 mg kg(-1) loading dose and 30 mg kg(-1) h(-1) infusion.
Number of subjects: 20
Study: 25586728

Group type: EXPERIMENTAL
Intervention: Surgical checklist use
Number of subjects: 45591
Study: 25586952

Group type: EXPERIMENTAL
Intervention: Escalating radiation dose with simultaneous integrated boost (SIB) to the pre-treatment 50% SUVmax area of the primary tumor, up to 70Gy
Number of subjects: 25
Study: 25587040

Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation (SCT) in first complete remission
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation (SCT) in patients with postinduction minimal residual disease (MRD) ≥10(-3)
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation (SCT) in B-cell precursor ALL patients with focal IKZF1 gene deletion
Number of subjects: 522

Group type: COMPARATOR
Intervention: No SCT
Number of subjects: 522
Study: 25589001

Group type: EXPERIMENTAL
Intervention: Weight gain (>1 BMI unit)
Number of subjects: 7169

Group type: COMPARATOR
Intervention: Stable weight (+/- 1 BMI unit)
Number of subjects: 7169

Group type: COMPARATOR
Intervention: Weight loss (<1 BMI unit)
Number of subjects: 7169

Group type: EXPERIMENTAL
Intervention: Baseline overweight
Number of subjects: 7169

Group type: EXPERIMENTAL
Intervention: Baseline obesity
Number of subjects: 7169
Study: 25589197

Group type: EXPERIMENTAL
Intervention: Usual care plus ICD therapy in REFINE-ICD
Number of subjects: 1001

Group type: COMPARATOR
Intervention: Usual care in REFINE-ICD
Number of subjects: 1001

Group type: EXPERIMENTAL
Intervention: Patients with DM in ARTEMIS
Number of subjects: 1001

Group type: COMPARATOR
Intervention: Patients without DM in ARTEMIS
Number of subjects: 1001

Group type: EXPERIMENTAL
Intervention: Patients with LVEF < 50% in ARTEMIS
Number of subjects: 1001

Group type: COMPARATOR
Intervention: Patients with LVEF ≥ 50% in ARTEMIS
Number of subjects: 1001

Group type: EXPERIMENTAL
Intervention: Patients with LVEF below the median of 42% in REFINE-ICD
Number of subjects: 1001

Group type: COMPARATOR
Intervention: Patients with LVEF above the median of 42% in REFINE-ICD
Number of subjects: 1001
Study: 25589213

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (weight reduction)
Number of subjects: 72
Study: 25589626

Group type: EXPERIMENTAL
Intervention: ChiLob7/4 (agonistic anti-CD40 antibody) at 200 mg × 4 doses, administered by IV infusion weekly for 4 doses.
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: ChiLob7/4 (agonistic anti-CD40 antibody) at doses above 16 mg.
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: ChiLob7/4 (agonistic anti-CD40 antibody) at doses between 1.6 mg and 50 mg.
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: ChiLob7/4 (agonistic anti-CD40 antibody) at doses that can be administered safely.
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: ChiLob7/4 (agonistic anti-CD40 antibody) at doses from 50 mg upward.
Number of subjects: 28
Study: 25590177

Group type: EXPERIMENTAL
Intervention: Magnetic-controlled capsule endoscopy (MCE)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Gastroscopy
Number of subjects: 68
Study: 25590214

Group type: EXPERIMENTAL
Intervention: Arterial norepinephrine concentration
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Calculated norepinephrine spillover rate
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Augmentation index (AI)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Insulin sensitivity (M)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Matsuda insulin sensitivity index
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Cardiac output
Number of subjects: 58

Group type: COMPARATOR
Intervention: Gender (female)
Number of subjects: 58
Study: 25590481

Group type: EXPERIMENTAL
Intervention: probe-based confocal laser endomicroscopy (pCLE)
Number of subjects: 6

Group type: COMPARATOR
Intervention: whole-lung lavage
Number of subjects: 6
Study: 25590835

Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg/day) and capecitabine (1000 mg/m2 twice daily on days 1-14)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Erlotinib plus capecitabine
Number of subjects: 58
Study: 25591040

Group type: EXPERIMENTAL
Intervention: Trabectedin 0.9 mg/m2 on day 1 and gemcitabine 700 mg/m2 on days 1 + 8, every 3 weeks
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Trabectedin 0.7 mg/m2 plus gemcitabine 700 mg/m2
Number of subjects: 5
Study: 25591505

Group type: EXPERIMENTAL
Intervention: Sofosbuvir and ledipasvir for 12 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sofosbuvir, ledipasvir, and GS-9669 for 6 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sofosbuvir, ledipasvir, and GS-9451 for 6 weeks
Number of subjects: 60
Study: 25592331

Group type: EXPERIMENTAL
Intervention: IV ibuprofen (800 mg) administered over 5 to 10 minutes preoperatively
Number of subjects: 300
Study: 25592341

Group type: EXPERIMENTAL
Intervention: Topical steroid treatment
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Systemic steroids
Number of subjects: 38
Study: 25592632

Group type: EXPERIMENTAL
Intervention: Sunitinib 50 mg orally once a day in 6-week cycles (4 weeks of treatment followed by 2 weeks without treatment)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 41
Study: 25592642

Group type: EXPERIMENTAL
Intervention: Pre-screening during multidisciplinary cancer (MDC) meetings
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Final review by the principal investigator (PI)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Systematic review by the clinical research assistant (CRA)
Number of subjects: 4

Group type: COMPARATOR
Intervention: MDC reports
Number of subjects: 4

Group type: COMPARATOR
Intervention: CRA proposals
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Proposal by the PI
Number of subjects: 4

Group type: COMPARATOR
Intervention: Proposal by the CRA
Number of subjects: 4
Study: 25592691

Group type: EXPERIMENTAL
Intervention: Coronary CTA with atherosclerotic plaque characteristics (APCs) including %APV, PR, LAP, SC
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Positive remodeling (PR)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Low attenuation plaque (LAP)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Spotty calcification (SC)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: 1 or more APCs
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: %APV and APCs by coronary CTA
Number of subjects: 252
Study: 25592974

Group type: EXPERIMENTAL
Intervention: Calcium ionophore activation combined with ICSI; oocytes stimulated with calcium ionophore for 30 minutes after ICSI.
Number of subjects: 2

Group type: COMPARATOR
Intervention: Non-activated oocytes (control group).
Number of subjects: 2
Study: 25593047

Group type: EXPERIMENTAL
Intervention: fMRI cue-reactivity in the ventral striatum (VS)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: fMRI cue-reactivity in the orbitofrontal cortex (OFC)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Data-aggregation measures that consider both spatial extent and intensity of cue-induced brain activation
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Measure defined as the sum of t-values exceeding an individually defined threshold
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Data collected in the VS
Number of subjects: 49
Study: 25593079

Group type: EXPERIMENTAL
Intervention: Intrathecal injection of CD133-positive enriched bone marrow progenitor cells
Number of subjects: 12
Study: 25593211

Group type: EXPERIMENTAL
Intervention: Acute Kidney Injury (AKI)
Number of subjects: 615

Group type: COMPARATOR
Intervention: Coronary angiographic procedures
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: Baseline variables (creatinine clearance and left ventricular ejection fraction)
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: AKI
Number of subjects: 615
Study: 25593303

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate and prednisone
Number of subjects: 348

Group type: COMPARATOR
Intervention: Prednisone
Number of subjects: 348
Study: 25593740

Group type: EXPERIMENTAL
Intervention: Bone marrow-derived human mesenchymal stem/stromal cells (MSCs)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 25593749

Group type: EXPERIMENTAL
Intervention: Low tidal volume ventilation with high PEEP
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group with lower PEEP strategy
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: NMB use
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Clinician comfort assessment
Number of subjects: 30
Study: 25594553

Group type: EXPERIMENTAL
Intervention: FCRx (facilitating cell enriched hematopoietic stem cell allografts)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Conventional immunosuppression (IS)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Transient or nonchimeric status
Number of subjects: 19
Study: 25594861

Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate (TU) treatment for 0.8 years (median 0.5; 1.3)
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Puberty nomogram
Number of subjects: 287
Study: 25594886

Group type: EXPERIMENTAL
Intervention: Sarcoidosis Assessment Tool (SAT)
Number of subjects: 173
Study: 25595221

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA treatment, mean dose 189.8 ± 87.1U, average treatment intervals of 14.6 and 15.1 weeks.
Number of subjects: 1046

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA treatment
Number of subjects: 1046
Study: 25595302

Group type: EXPERIMENTAL
Intervention: Chronic pain
Number of subjects: 250
Study: 25595315

Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch
Number of subjects: 75
Study: 25595400

Group type: EXPERIMENTAL
Intervention: Fenestrated/branched repair techniques
Number of subjects: 49
Study: 25595936

Group type: COMPARATOR
Intervention: HOXB13 G84E variant in PrCa cases (1.5%) vs healthy controls (0.5%)
Number of subjects: 13904

Group type: COMPARATOR
Intervention: Family history of PrCa
Number of subjects: 13904

Group type: COMPARATOR
Intervention: Young-onset PrCa (diagnosed up to age 55)
Number of subjects: 13904

Group type: COMPARATOR
Intervention: HOXB13 G84E variant
Number of subjects: 13904

Group type: COMPARATOR
Intervention: Polygenic PrCa risk score (PR score) including HOXB13 G84E variant
Number of subjects: 13904
Study: 25596263

Group type: EXPERIMENTAL
Intervention: Vorinostat 200 mg orally twice daily on days 1-14 and rituximab 375 mg/m² intravenously on day 1 of a 21-day cycle.
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Vorinostat/rituximab regimen
Number of subjects: 28
Study: 25596264

Group type: EXPERIMENTAL
Intervention: Ofatumumab
Number of subjects: 103
Study: 25596270

Group type: EXPERIMENTAL
Intervention: Subcutaneous bortezomib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous bortezomib
Number of subjects: 0
Study: 25596313

Group type: EXPERIMENTAL
Intervention: Simeprevir (SMV) 150mg QD + peginterferon-α-2a/ribavirin (PR) for 12 weeks, followed by PR alone for 12 or 36 weeks.
Number of subjects: 107
Study: 25596730

Group type: EXPERIMENTAL
Intervention: Flavopiridol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Knockdown of Mcl-1
Number of subjects: 0
Study: 25599334

Group type: EXPERIMENTAL
Intervention: MVPA assessed via SenseWear Armband (MVPAOBJ)
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Self-reported MVPA via Paffenbarger Questionnaire (MVPAPAFF)
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Self-reported MVPA via Global Physical Activity Questionnaire (GPAQ)
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Self-reported MVPA from transportation and recreation (MVPAGPAQ-REC)
Number of subjects: 448
Study: 25599347

Group type: EXPERIMENTAL
Intervention: HAART initiated during pregnancy
Number of subjects: 671

Group type: EXPERIMENTAL
Intervention: HAART initiated in the third trimester
Number of subjects: 671

Group type: EXPERIMENTAL
Intervention: Multiparity
Number of subjects: 671

Group type: EXPERIMENTAL
Intervention: Black ethnicity
Number of subjects: 671

Group type: EXPERIMENTAL
Intervention: 11th grade education or less
Number of subjects: 671

Group type: EXPERIMENTAL
Intervention: HIV diagnosis before current pregnancy
Number of subjects: 671

Group type: EXPERIMENTAL
Intervention: First prenatal visit in the third trimester
Number of subjects: 671

Group type: EXPERIMENTAL
Intervention: Treatment interruptions or poor medication adherence
Number of subjects: 671
Study: 25599365

Group type: EXPERIMENTAL
Intervention: Bisphosphonates
Number of subjects: 0
Study: 25599695

Group type: EXPERIMENTAL
Intervention: Crush the Crave mobile phone app
Number of subjects: 1354

Group type: COMPARATOR
Intervention: On the Road to Quitting self-help guide
Number of subjects: 1354
Study: 25599806

Group type: EXPERIMENTAL
Intervention: Foetuses with congenital heart disease (CHD)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Foetuses with normal anatomy (Control)
Number of subjects: 92
Study: 25599824

Group type: EXPERIMENTAL
Intervention: PGS using comprehensive chromosome screening after blastocyst biopsy (PGS-v2)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Routine IVF care
Number of subjects: 3
Study: 25600030

Group type: EXPERIMENTAL
Intervention: PCOS women (lean)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Overweight/obese PCOS patients (all phenotypes)
Number of subjects: 300

Group type: COMPARATOR
Intervention: PCOS women (all phenotypes)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Evaluated CVD risk (all phenotypes)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 2 of 4 Rotterdam phenotypes
Number of subjects: 300
Study: 25600335

Group type: EXPERIMENTAL
Intervention: Fenestrated/branched endovascular repair
Number of subjects: 924
Study: 25603113

Group type: EXPERIMENTAL
Intervention: Oral washes (OW)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Induced sputa (IS)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Bronchoalveolar lavages (BAL)
Number of subjects: 56
Study: 25603463

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) surgery
Number of subjects: 11
Study: 25603819

Group type: EXPERIMENTAL
Intervention: Liraglutide (dose range 0.3-1.8 mg)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 13
Study: 25603823

Group type: EXPERIMENTAL
Intervention: Elevated interferon-α (IFNα) levels in SLE patients with poor pregnancy outcomes
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Low IFNα levels in SLE patients
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: High IFNα levels in SLE patients
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Combination of IFNα and soluble Flt-1
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Soluble Flt-1 treatment on human endothelial cells
Number of subjects: 28
Study: 25603822

Group type: EXPERIMENTAL
Intervention: Suboxone 2.0/0.5-mg tablet
Number of subjects: 43
Study: 25604319

Group type: EXPERIMENTAL
Intervention: Higher knee OA x-ray grade
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: Gender differences in clinical scores
Number of subjects: 518
Study: 25604779

Group type: EXPERIMENTAL
Intervention: Preoperative oral nutritional supplements (ingestion of ⩾ 11/15 units)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Preoperative oral nutritional supplements
Number of subjects: 141
Study: 25605003

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) treatment
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Adalimumab treatment
Number of subjects: 56
Study: 25605368

Group type: EXPERIMENTAL
Intervention: Mogamulizumab (1.0 mg/kg)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Mogamulizumab (0.1, 0.3, and 1.0 mg/kg)
Number of subjects: 41
Study: 25605552

Group type: EXPERIMENTAL
Intervention: Once-daily trientine (15 mg/kg)
Number of subjects: 8
Study: 25605745

Group type: EXPERIMENTAL
Intervention: Romidepsin at a dose of 14 mg/m(2) on days 1, 8, and 15 of 28-day cycles
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Romidepsin treatment
Number of subjects: 130
Study: 25605853

Group type: EXPERIMENTAL
Intervention: Early screening MRI at 6.5 and 9 months from diagnosis
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Early screening MRI
Number of subjects: 498
Study: 25605857

Group type: EXPERIMENTAL
Intervention: Minimal Residual Disease (MRD) assessment at days +30, +60, +90, +180, and +365 after transplantation
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: MRD assessment
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: MRD ≥ 10(-4) leukemic cells
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: MRD detection
Number of subjects: 113
Study: 25608607

Group type: EXPERIMENTAL
Intervention: Thromboprophylaxis in high-risk patients (Geneva Risk Score ≥ 3 points)
Number of subjects: 1478

Group type: EXPERIMENTAL
Intervention: Thromboprophylaxis in low-risk patients (Geneva Risk Score < 3 points)
Number of subjects: 1478
Study: 25608692

Group type: EXPERIMENTAL
Intervention: Alive-PD program (1-year, fully automated behavior change program delivered by email and Web)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Alive-PD program
Number of subjects: 340

Group type: COMPARATOR
Intervention: Delayed-entry control group
Number of subjects: 340
Study: 25609248

Group type: EXPERIMENTAL
Intervention: OPB-51602 at 5 mg intermittently
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: OPB-51602 at 4 mg continuously
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: OPB-51602 at 4 mg intermittently (Cohort B)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: OPB-51602 at 2 mg and 4 mg intermittently
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Continuous dosing of OPB-51602
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Intermittent dosing of OPB-51602
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: OPB-51602
Number of subjects: 51
Study: 25609320

Group type: EXPERIMENTAL
Intervention: Quetiapine XR (300 mg on day 1, 600 mg on day 2, adjusted to 400-800 mg thereafter)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Quetiapine XR
Number of subjects: 61